Table 1.
Baseline Clinical and demographic features of the sample as a whole and by dose group.
| All mean (std) or N (%)(N=119) | High dose mean (std) or N (%)(N=58) | Low dose mean (std) or N (%)(N=61) | T or χ2 | p | |
|---|---|---|---|---|---|
| Age (yrs) | 46.9 (10.1) | 45.3(10.6) | 48.5(9.4) | 1.7 | 0.086 |
| Female (%) | 81.5 | 84.5 | 78.7 | 0.7 | 0.416 |
| Race | 1.4 | 0.703 | |||
| White (%) | 87.4 | 86.2 | 88.5 | ||
| Black (%) | 10.1 | 12.1 | 8.2 | ||
| Hisp (%) | 3.4 | 5.2 | 1.6 | ||
| Other (%) | 4.2 | 1.7 | 6.6 | ||
| Age of Onset (yrs) | 27.1(11.1) | 27.0(10.2) | 27.1(12.0) | 0.0 | 0.988 |
| Current Episode (Months) | 81.5(96.8) | 73.1(95.0) | 89.6(98.5) | 0.9 | 0.354 |
| Weeks on SSRIa | 7.9(6.7) | 9.1(8.4) | 6.7(4.1) | −1. 8 | 0.075 |
| SSRI | 4.0 | 0.552 | |||
| Citalopram (%) | 3.4 | 3.4 | 3.3 | ||
| Escitalopram (%) | 73.9 | 75.9 | 72.1 | ||
| Fluoxetine (%) | 3. | 1.7 | 4.9 | ||
| Paroxetine CR (%) | 3.4 | 5.2 | 1.6 | ||
| Paroxetine (%) | 1.7 | 0.0 | 3.3 | ||
| Sertraline (%) | 14.3 | 13.8 | 14.8 | ||
| QIDS-C | 14.0(2.6) | 14.0(2.5) | 14.0(2.6) | 0.0 | 0.972 |
| QIDS-SR | 12.6(4.0) | 12.2(3.6) | 13.0(4.3) | 1.1 | 0.276 |
| Weight (kg) | 87.3(20.2) | 86.8(22.7) | 87.8(17.7) | 0.3 | 0.777 |
| BMI | 30.9 (6.0) | 30.3(6.5) | 31.4(5.5) | 1.0 | 0.325 |
| VO2 max (lmin) | 1.7 (0.6) | 1.7(0.5) | 1.7(0.7) | 0.6 | 0.569 |
| SHAPS total score | 3.1(3.0) | 2.8(3.1) | 3.4(3.0) | 1.0 | 0.329 |
| MEI total score | 34.7(14.4) | 34.4(12.5) | 34.9(16.0) | 0.2 | 0.854 |
| MEI mental energy | 19.0(8.6) | 18.9(7.9) | 19.1(9.3) | 0.1 | 0.916 |
| MEI social Motivation | 9.9(5.3) | 9.7(5.0) | 10.0(5.7) | 0.3 | 0.768 |
| MEI physical Energy | 4.9(3.3) | 5.0(2.9) | 4.8(3.7) | −0.2 | 0.809 |
a
Length of SSRI trial at baseline. Subjects maintained SSRI treatment during the 12 week study.